ES2475201T3 - Agentes dirigidos contra CD138 y usos de los mismos - Google Patents

Agentes dirigidos contra CD138 y usos de los mismos Download PDF

Info

Publication number
ES2475201T3
ES2475201T3 ES08863602.2T ES08863602T ES2475201T3 ES 2475201 T3 ES2475201 T3 ES 2475201T3 ES 08863602 T ES08863602 T ES 08863602T ES 2475201 T3 ES2475201 T3 ES 2475201T3
Authority
ES
Spain
Prior art keywords
antibody
nbt062
cells
seq
immunoconjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08863602.2T
Other languages
English (en)
Spanish (es)
Inventor
Elmar Kraus
Christoph Bruecher
Benjamin Daelken
Matthias Germer
Steffen Zeng
Frank Osterroth
Christoph Uherek
Silke Aigner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biotest AG
Original Assignee
Biotest AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40456217&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2475201(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biotest AG filed Critical Biotest AG
Application granted granted Critical
Publication of ES2475201T3 publication Critical patent/ES2475201T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
ES08863602.2T 2007-12-26 2008-12-23 Agentes dirigidos contra CD138 y usos de los mismos Active ES2475201T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1663007P 2007-12-26 2007-12-26
US16630P 2007-12-26
PCT/EP2008/068266 WO2009080829A1 (fr) 2007-12-26 2008-12-23 Agents ciblant cd138 et leurs applications

Publications (1)

Publication Number Publication Date
ES2475201T3 true ES2475201T3 (es) 2014-07-10

Family

ID=40456217

Family Applications (2)

Application Number Title Priority Date Filing Date
ES08863602.2T Active ES2475201T3 (es) 2007-12-26 2008-12-23 Agentes dirigidos contra CD138 y usos de los mismos
ES14170861T Active ES2748299T3 (es) 2007-12-26 2008-12-23 Agentes dirigidos contra CD138 y usos de los mismos

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES14170861T Active ES2748299T3 (es) 2007-12-26 2008-12-23 Agentes dirigidos contra CD138 y usos de los mismos

Country Status (23)

Country Link
US (2) US9221914B2 (fr)
EP (2) EP2801584B1 (fr)
JP (2) JP5990365B2 (fr)
KR (1) KR101626416B1 (fr)
CN (1) CN101952315B (fr)
AR (1) AR069981A1 (fr)
AU (1) AU2008339910B2 (fr)
BR (1) BRPI0821447A2 (fr)
CA (1) CA2710453C (fr)
CR (1) CR11593A (fr)
DK (1) DK2238168T3 (fr)
ES (2) ES2475201T3 (fr)
HK (2) HK1149033A1 (fr)
HR (1) HRP20140604T1 (fr)
IL (1) IL206554A (fr)
MX (1) MX341344B (fr)
PL (2) PL2801584T3 (fr)
PT (1) PT2238168E (fr)
RU (1) RU2537265C2 (fr)
SI (1) SI2238168T1 (fr)
TW (1) TWI552759B (fr)
WO (1) WO2009080829A1 (fr)
ZA (1) ZA201004325B (fr)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060045877A1 (en) * 2004-08-30 2006-03-02 Goldmakher Viktor S Immunoconjugates targeting syndecan-1 expressing cells and use thereof
PL2801584T3 (pl) 2007-12-26 2019-12-31 Biotest Ag Środki mające za cel CD138 i ich zastosowania
EP2240516B1 (fr) * 2007-12-26 2015-07-08 Biotest AG Procédés et agents permettant d'améliorer le ciblage de cellules tumorales exprimant cd138
CN101965366B (zh) * 2007-12-26 2016-04-27 生物测试股份公司 靶向cd138的免疫缀合物及其应用
SG10201401976YA (en) * 2009-05-06 2014-10-30 Biotest Ag Uses of immunoconjugates targeting cd138
AU2013201618B2 (en) * 2009-05-06 2016-06-02 Biotest Ag Uses of immunoconjugates targeting CD138
EP2699268A2 (fr) 2011-04-21 2014-02-26 Seattle Genetics, Inc. Nouveaux conjugués liant-principe actif (adc) et leur utilisation
EP3559049A4 (fr) 2011-10-28 2019-12-04 Teva Pharmaceuticals Australia Pty Ltd Produits de recombinaison de polypeptide et utilisations de ceux-ci
EP2788030B1 (fr) 2011-12-08 2018-06-20 Biotest AG Utilisations d'immunoconjugués ciblant cd138
CN104837502B (zh) 2012-10-12 2018-08-10 麦迪穆有限责任公司 吡咯并苯并二氮杂卓及其结合物
CN103103197A (zh) * 2013-01-30 2013-05-15 百奇生物科技（苏州）有限公司 抗cd138单克隆抗体可变区序列及其制备方法和应用
WO2014138704A1 (fr) * 2013-03-07 2014-09-12 Baylor College Of Medicine Ciblage de cd138 dans le cancer
JP6444902B2 (ja) 2013-03-13 2018-12-26 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン及びその結合体
AU2013388126B2 (en) 2013-04-29 2019-03-07 Teva Pharmaceuticals Australia Pty Ltd. Anti-CD38 antibodies and fusions to attenuated interferon alpha-2b
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
NZ720736A (en) 2013-12-23 2020-08-28 Bayer Pharma AG Antibody drug conjugates (adcs) with kinesin spindel protein (ksp)
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
ES2785551T3 (es) 2014-06-30 2020-10-07 Glykos Finland Oy Derivado de sacárido de una carga útil tóxica y sus conjugados con anticuerpos
JP7113618B2 (ja) 2014-07-15 2022-08-05 ジュノー セラピューティクス インコーポレイテッド 養子細胞療法用の操作された細胞
US10648554B2 (en) 2014-09-02 2020-05-12 Polaris Industries Inc. Continuously variable transmission
US10188746B2 (en) 2014-09-10 2019-01-29 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
KR102639037B1 (ko) 2014-10-29 2024-02-20 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 인터페론 α2b 변이체
TWI588259B (zh) * 2015-03-06 2017-06-21 Methods for screening antigen-specific fusion tumor cells
CN108025084A (zh) 2015-06-22 2018-05-11 拜耳医药股份有限公司 具有酶可裂解基团的抗体药物缀合物（adc）和抗体前药缀合物（apdc）
MA42895A (fr) 2015-07-15 2018-05-23 Juno Therapeutics Inc Cellules modifiées pour thérapie cellulaire adoptive
RU2611685C2 (ru) * 2015-07-20 2017-02-28 Илья Владимирович Духовлинов Гуманизированное моноклональное антитело, специфичное к синдекану-1
WO2017060322A2 (fr) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Conjugué anticorps-médicament (adc) inhibiteur de ptefb
WO2017162663A1 (fr) 2016-03-24 2017-09-28 Bayer Pharma Aktiengesellschaft Promédicaments de principes actifs cytotoxiques contenant des groupes fissibles par voie enzymatique
JP7022707B2 (ja) 2016-06-15 2022-02-18 バイエル・ファルマ・アクティエンゲゼルシャフト Ｋｓｐ阻害剤および抗ｃｄ１２３抗体を含む特異的抗体－薬物－コンジュゲート（ａｄｃ）
EP3525829A1 (fr) 2016-10-11 2019-08-21 Medimmune Limited Conjugués anticorps-médicament associés à des agents thérapeutiques à médiation immunitaire
CN110072556B (zh) 2016-12-21 2023-05-02 拜耳制药股份公司 具有ksp抑制剂的特异性抗体药物缀合物(adc)
WO2018114798A1 (fr) 2016-12-21 2018-06-28 Bayer Aktiengesellschaft Promédicaments de principes actifs cytotoxiques contenant des groupes divisibles par voie enzymatique
KR102583006B1 (ko) 2016-12-21 2023-09-27 바이엘 파마 악티엔게젤샤프트 효소적으로 절단가능한 기를 갖는 항체 약물 접합체 (adc)
US10697532B2 (en) 2016-12-22 2020-06-30 Polaris Industries Inc. Housing for a transmission
WO2018199176A1 (fr) * 2017-04-26 2018-11-01 Mitsubishi Tanabe Pharma Corporation Agents de liaison à syndécane-1 (cd138) et leurs utilisations
EP3619535A4 (fr) 2017-05-05 2020-12-30 University of Technology Sydney Procédé de pronostic du cancer
DK3538645T3 (da) 2017-06-20 2021-04-19 Inst Curie Immunceller der mangler suv39h1
BR112020005419A2 (pt) * 2017-10-02 2020-09-29 Visterra, Inc. moléculas de anticorpo para cd138 e seus usos
AU2018360801A1 (en) 2017-11-01 2020-05-14 Celgene Corporation Process for producing a T cell composition
EP3703688A2 (fr) 2017-11-01 2020-09-09 Juno Therapeutics, Inc. Anticorps et récepteurs antigéniques chimériques spécifiques de l'antigene de maturation des lymphocytes b
WO2019089858A2 (fr) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Procédés d'évaluation ou de surveillance d'une réponse à une thérapie cellulaire
US11564946B2 (en) 2017-11-01 2023-01-31 Juno Therapeutics, Inc. Methods associated with tumor burden for assessing response to a cell therapy
WO2019090003A1 (fr) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Récepteurs d'antigènes chimériques spécifiques de l'antigène de maturation des cellules b (bcma)
CA3084514A1 (fr) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Procede de generation de compositions therapeutiques de cellules modifiees
WO2019111249A1 (fr) 2017-12-05 2019-06-13 The Medical Research Infrastructure And Health Services Fund Of The Tel Aviv Medical Center Lymphocytes t comprenant des récepteurs antigéniques chimériques anti-cd38 et anti-cd138 et leurs utilisations
WO2019113556A1 (fr) 2017-12-08 2019-06-13 Juno Therapeutics, Inc. Formulation de milieux sans sérum pour la culture de cellules et ses procédés d'utilisation
EP3720480A2 (fr) 2017-12-08 2020-10-14 Juno Therapeutics, Inc. Marqueurs phénotypiques pour thérapie cellulaire et procédés associés
SG11202005272SA (en) 2017-12-08 2020-07-29 Juno Therapeutics Inc Process for producing a composition of engineered t cells
CA3183788A1 (fr) 2018-03-19 2019-09-26 Polaris Industries Inc. Transmission a variation continue
CA3094207C (fr) 2018-03-19 2023-03-07 Ronald ZURBRUEGG Cvt electronique avec embrayage a friction
CN113286616A (zh) 2018-05-23 2021-08-20 Adc治疗有限公司 分子佐剂
EP3833759A1 (fr) 2018-08-09 2021-06-16 Juno Therapeutics, Inc. Procédés pour évaluer des acides nucléiques intégrés
JP2022506598A (ja) 2018-11-01 2022-01-17 ジュノー セラピューティクス インコーポレイテッド Ｇタンパク質共役受容体クラスｃグループ５メンバーｄ（ｇｐｒｃ５ｄ）に特異的なキメラ抗原受容体
WO2020092848A2 (fr) 2018-11-01 2020-05-07 Juno Therapeutics, Inc. Méthodes pour le traitement au moyen de récepteurs antigéniques chimériques spécifiques de l'antigene de maturation des lymphocytes b
WO2020223571A1 (fr) 2019-05-01 2020-11-05 Juno Therapeutics, Inc. Cellules exprimant un récepteur chimérique à partir d'un locus cd247 modifié, polynucléotides et procédés associés
KR20220016475A (ko) 2019-05-01 2022-02-09 주노 쎄러퓨티크스 인코퍼레이티드 변형된 ｔｇｆｂｒ2 유전자 좌에서 재조합 수용체를 발현하는 세포, 관련 폴리뉴클레오티드 및 방법
KR20220044939A (ko) * 2019-06-17 2022-04-12 비스테라, 인크. Cd138에 대한 인간화 항체 분자 및 이의 용도
CA3146895A1 (fr) 2019-07-23 2021-01-28 Mnemo Therapeutics Cellules immunitaires defectueuses pour suv39h1
KR102287180B1 (ko) 2019-10-01 2021-08-09 충북대학교 산학협력단 Cd138에 특이적으로 결합하는 키메릭 항원 수용체, 이를 발현하는 면역세포 및 이의 항암 용도
CN115916223A (zh) 2020-04-10 2023-04-04 朱诺治疗学股份有限公司 与用靶向b细胞成熟抗原的嵌合抗原受体工程化的细胞疗法相关的方法和用途
EP4150640A1 (fr) 2020-05-13 2023-03-22 Juno Therapeutics, Inc. Procédés d'identification de caractéristiques associées à une réponse clinique et leurs utilisations
JP2023531531A (ja) 2020-06-26 2023-07-24 ジュノ セラピューティクス ゲーエムベーハー 組換え受容体を条件付きで発現する操作されたｔ細胞、関連ポリヌクレオチド、および方法
CN116096864A (zh) 2020-07-30 2023-05-09 居里研究所 Socs1缺陷的免疫细胞
WO2022079211A1 (fr) 2020-10-16 2022-04-21 Adc Therapeutics Sa Glycoconjugués
CN116802203A (zh) 2020-11-04 2023-09-22 朱诺治疗学股份有限公司 从经修饰的恒定cd3免疫球蛋白超家族链基因座表达嵌合受体的细胞、相关多核苷酸和方法
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
WO2022187406A1 (fr) 2021-03-03 2022-09-09 Juno Therapeutics, Inc. Combinaison d'une thérapie par lymphocytes t et d'un inhibiteur de dgk
JP2024517863A (ja) 2021-05-06 2024-04-23 ジュノ・セラピューティクス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 細胞を刺激し、形質導入する方法
EP4337763A1 (fr) 2021-05-10 2024-03-20 Institut Curie Procédés de traitement du cancer, de maladies inflammatoires et de maladies auto-immunes
EP4346912A1 (fr) 2021-05-25 2024-04-10 Institut Curie Cellules myéloïdes surexprimant bcl2
WO2023126458A1 (fr) 2021-12-28 2023-07-06 Mnemo Therapeutics Cellules immunitaires avec suv39h1 inactivé et tcr modifié
WO2023147515A1 (fr) 2022-01-28 2023-08-03 Juno Therapeutics, Inc. Procédés de fabrication de compositions cellulaires
WO2023159182A1 (fr) 2022-02-18 2023-08-24 Rakuten Medical, Inc. Molécules d'anticorps anti-ligand de mort cellulaire programmée 1 (pd-l1), polynucléotides de codage et méthodes d'utilisation
WO2023187024A1 (fr) 2022-03-31 2023-10-05 Institut Curie Protéine rela modifiée pour induire l'expression d'interféron et cellules immunitaires modifiées ayant une expression d'interféron améliorée
WO2023213969A1 (fr) 2022-05-05 2023-11-09 Juno Therapeutics Gmbh Protéine de liaison virale et réactifs, articles et méthodes d'utilisation associés
WO2023220655A1 (fr) 2022-05-11 2023-11-16 Celgene Corporation Méthodes pour surmonter la résistance aux médicaments par ré-sensibilisation de cellules cancéreuses à un traitement avec une thérapie antérieure par l'intermédiaire d'un traitement avec une thérapie par lymphocytes t
WO2023230581A1 (fr) 2022-05-25 2023-11-30 Celgene Corporation Procédés de fabrication de thérapies par lymphocytes t
WO2023230548A1 (fr) 2022-05-25 2023-11-30 Celgene Corporation Procédé de prédiction d'une réponse à une thérapie par lymphocyte t
WO2024054944A1 (fr) 2022-09-08 2024-03-14 Juno Therapeutics, Inc. Combinaison de thérapie cellulaire t et de dosage continu ou intermittent d'inhibiteurs de dgk
WO2024100604A1 (fr) 2022-11-09 2024-05-16 Juno Therapeutics Gmbh Procédés de fabrication de cellules immunitaires modifiées
WO2024102954A1 (fr) 2022-11-10 2024-05-16 Massachusetts Institute Of Technology Système d'écrêtage induit par activation (aics)

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3896111A (en) 1973-02-20 1975-07-22 Research Corp Ansa macrolides
US4151042A (en) * 1977-03-31 1979-04-24 Takeda Chemical Industries, Ltd. Method for producing maytansinol and its derivatives
US4169888A (en) 1977-10-17 1979-10-02 The Upjohn Company Composition of matter and process
US4137230A (en) 1977-11-14 1979-01-30 Takeda Chemical Industries, Ltd. Method for the production of maytansinoids
US4265814A (en) * 1978-03-24 1981-05-05 Takeda Chemical Industries Matansinol 3-n-hexadecanoate
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
JPS5562090A (en) 1978-10-27 1980-05-10 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164687A (en) * 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS5566585A (en) * 1978-11-14 1980-05-20 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS55102583A (en) * 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en) * 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS55164685A (en) 1979-06-08 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164686A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4309428A (en) * 1979-07-30 1982-01-05 Takeda Chemical Industries, Ltd. Maytansinoids
JPS5645483A (en) * 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
EP0028683A1 (fr) * 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotique C-15003 PHO et sa préparation
JPS5645485A (en) 1979-09-21 1981-04-25 Takeda Chem Ind Ltd Production of c-15003pnd
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
WO1982001188A1 (fr) 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd Composes 4,5-deoxymaytansinoide et leur procede de preparation
US4315929A (en) * 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
US4313946A (en) * 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
US4563304A (en) 1981-02-27 1986-01-07 Pharmacia Fine Chemicals Ab Pyridine compounds modifying proteins, polypeptides or polysaccharides
JPS57192389A (en) 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
US4761111A (en) * 1981-09-18 1988-08-02 Brown Andrew M Automobile lifting and towing equipment
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US4418064A (en) * 1982-09-29 1983-11-29 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids: treflorine, trenudine, and N-methyltrenudone
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
WO1988002594A2 (fr) 1986-10-09 1988-04-21 Neorx Corporation Procedes permettant d'ameliorer le ciblage d'anticorps, de fragments d'anticorps, d'hormones et autres agents de ciblage, et leurs conjugues
US5053394A (en) 1988-09-21 1991-10-01 American Cyanamid Company Targeted forms of methyltrithio antitumor agents
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5208020A (en) * 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
SG48759A1 (en) 1990-01-12 2002-07-23 Abgenix Inc Generation of xenogenic antibodies
WO1991016324A1 (fr) * 1990-04-25 1991-10-31 The Upjohn Company Nouveaux analogues de cc-1065
US5814318A (en) * 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
US6407213B1 (en) * 1991-06-14 2002-06-18 Genentech, Inc. Method for making humanized antibodies
US5998656A (en) 1991-09-23 1999-12-07 Florida State University C10 tricyclic taxanes
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US6080777A (en) * 1992-01-31 2000-06-27 The Trustees Of Columbia University In The City Of New York Taxol as a radiation sensitizer
US5200534A (en) 1992-03-13 1993-04-06 University Of Florida Process for the preparation of taxol and 10-deacetyltaxol
ES2149768T3 (es) 1992-03-25 2000-11-16 Immunogen Inc Conjugados de agentes enlazantes de celulas derivados de cc-1065.
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
US5639641A (en) * 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5703247A (en) 1993-03-11 1997-12-30 Virginia Tech Intellectual Properties, Inc. 2-Debenzoyl-2-acyl taxol derivatives and methods for making same
US5475011A (en) 1993-03-26 1995-12-12 The Research Foundation Of State University Of New York Anti-tumor compounds, pharmaceutical compositions, methods for preparation thereof and for treatment
US6740734B1 (en) * 1994-01-14 2004-05-25 Biovitrum Ab Bacterial receptor structures
SE9400088D0 (sv) * 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
US5773001A (en) * 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5763477A (en) 1994-07-22 1998-06-09 Dr. Reddy's Research Foundation Taxane derivatives from 14-β-hydroxy-10 deacetylbaccatin III
AU5305796A (en) 1995-03-10 1996-10-02 Hauser Chemical Research, Inc. Cephalomannine epoxide, its analogues and a method for preparing the same
EP1978033A3 (fr) 1995-04-27 2008-12-24 Amgen Fremont Inc. Anticorps humains dérivés à partir de xénosouris immunisée
CA2219486A1 (fr) 1995-04-28 1996-10-31 Abgenix, Inc. Anticorps humains derives de xeno-souris immunisees
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
WO1997011971A1 (fr) * 1995-09-28 1997-04-03 Alexion Pharmaceuticals, Inc. Proteines d'interaction de cellules porcines
US6001358A (en) * 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
ES2301183T3 (es) 1996-12-03 2008-06-16 Amgen Fremont Inc. Anticuerpo completamente humano que se une al receptor del egfr.
RU2224766C2 (ru) 1997-04-14 2004-02-27 Микромет Аг Способ получения рецепторов для человеческих антигенов и их применение
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6962702B2 (en) * 1998-06-22 2005-11-08 Immunomedics Inc. Production and use of novel peptide-based agents for use with bi-specific antibodies
US6087362A (en) * 1999-03-16 2000-07-11 Pentech Pharmaceuticals, Inc. Apomorphine and sildenafil composition
NZ517772A (en) 1999-11-24 2004-03-26 Immunogen Inc Cytotoxic agents comprising taxanes and their therapeutic use
US20030203451A1 (en) * 2000-08-24 2003-10-30 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
US6333410B1 (en) * 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
WO2002016602A2 (fr) 2000-08-24 2002-02-28 Genentech, Inc. Compositions et procedes conçus pour le diagnostic et le traitement de tumeur
DE60136281D1 (de) 2000-08-24 2008-12-04 Genentech Inc Methode zur inhibierung von il-22 induziertem pap1
US6441163B1 (en) * 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
HUP0700103A3 (en) 2001-08-03 2012-09-28 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
US6716821B2 (en) * 2001-12-21 2004-04-06 Immunogen Inc. Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
US20040002587A1 (en) * 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US6534660B1 (en) 2002-04-05 2003-03-18 Immunogen, Inc. CC-1065 analog synthesis
US6756397B2 (en) 2002-04-05 2004-06-29 Immunogen, Inc. Prodrugs of CC-1065 analogs
PL224150B1 (pl) 2002-05-02 2016-11-30 Wyeth Corp Kompozycja zawierająca koniugat leku obejmujący pochodne kalicheamycyny i przeciwciało, oraz kompozycja farmaceutyczna ją zawierająca
US6596757B1 (en) 2002-05-14 2003-07-22 Immunogen Inc. Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use
US7390898B2 (en) 2002-08-02 2008-06-24 Immunogen Inc. Cytotoxic agents containing novel potent taxanes and their therapeutic use
US20040126379A1 (en) * 2002-08-21 2004-07-01 Boehringer Ingelheim International Gmbh Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents
US8367374B2 (en) * 2003-01-22 2013-02-05 Roche Glycart Ag Fusion constructs and use of same to produce antibodies with increased Fc receptor binding affinity and effector function
CA2525029A1 (fr) 2003-05-02 2004-11-18 Health Research, Inc. Utilisation de l'expression de jag2 dans le diagnostic de troubles de cellules plasmiques
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
CN103145844B (zh) * 2003-07-21 2016-08-03 伊缪诺金公司 Ca6抗原特异性细胞毒性偶联物及其应用方法
US20050027128A1 (en) * 2003-07-30 2005-02-03 Robbins Timothy A. Substituted thiazoles
KR101200188B1 (ko) * 2003-12-25 2012-11-13 교와 핫꼬 기린 가부시키가이샤 항 ｃｄ４０ 항체의 변이체
BRPI0510883B8 (pt) * 2004-06-01 2021-05-25 Genentech Inc composto conjugado de droga e anticorpo, composição farmacêutica, método de fabricação de composto conjugado de droga e anticorpo e usos de uma formulação, de um conjugado de droga e anticorpo e um agente quimioterapêutico e de uma combinação
RU2398882C2 (ru) 2004-07-22 2010-09-10 Эрасмус Юниверсити Медикал Сентр Роттердам СПОСОБ ПОЛУЧЕНИЯ АНТИГЕН-СВЯЗЫВАЮЩЕГО ДОМЕНА Vh ИСПОЛЬЗОВАНИЕ
US20060045877A1 (en) * 2004-08-30 2006-03-02 Goldmakher Viktor S Immunoconjugates targeting syndecan-1 expressing cells and use thereof
EP1810979B1 (fr) * 2004-09-22 2012-06-20 Kyowa Hakko Kirin Co., Ltd. ANTICORPS IgG4 HUMAINS STABILISES
SI2567976T1 (sl) 2005-03-23 2017-11-30 Genmab A/S Protitelesa usmerjena proti cd38 za zdravljenje multiplega mieloma
JP2008535491A (ja) 2005-04-07 2008-09-04 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド 癌に関連した遺伝子（ＰＴＰε）
EA200702239A1 (ru) 2005-04-15 2008-10-30 Иммьюноджен, Инк. Уничтожение гетерогенной или смешанной клеточной популяции в опухолях
US20070054332A1 (en) 2005-08-10 2007-03-08 Alan Rapraeger Syndecan 1 ectodomain inhibits cancer
CN101426815A (zh) * 2005-12-06 2009-05-06 杜门蒂斯有限公司 具有表皮生长因子受体和/或血管内皮生长因子结合特异性的配体及其使用方法
JP5624276B2 (ja) 2006-03-31 2014-11-12 中外製薬株式会社 抗体の血中動態を制御する方法
WO2007144046A2 (fr) 2006-05-03 2007-12-21 Elke Pogge Von Strandmann Agent de traitement de pathologies malignes
EP2240516B1 (fr) 2007-12-26 2015-07-08 Biotest AG Procédés et agents permettant d'améliorer le ciblage de cellules tumorales exprimant cd138
WO2009080831A1 (fr) * 2007-12-26 2009-07-02 Biotest Ag Procédé permettant de réduire les effets secondaires cytotoxiques et d'améliorer l'efficacité des immunoconjugués
PL2801584T3 (pl) 2007-12-26 2019-12-31 Biotest Ag Środki mające za cel CD138 i ich zastosowania
SG10201401976YA (en) 2009-05-06 2014-10-30 Biotest Ag Uses of immunoconjugates targeting cd138

Also Published As

Publication number Publication date
IL206554A (en) 2015-09-24
ZA201004325B (en) 2011-03-30
CA2710453C (fr) 2019-07-02
HRP20140604T1 (hr) 2014-09-12
PL2238168T3 (pl) 2014-11-28
AU2008339910B2 (en) 2014-01-09
JP5990365B2 (ja) 2016-09-14
CN101952315A (zh) 2011-01-19
BRPI0821447A2 (pt) 2015-06-16
WO2009080829A1 (fr) 2009-07-02
US9221914B2 (en) 2015-12-29
US20090175863A1 (en) 2009-07-09
DK2238168T3 (da) 2014-08-25
HK1203973A1 (en) 2015-11-06
EP2801584B1 (fr) 2019-07-10
JP2015143228A (ja) 2015-08-06
JP2011509245A (ja) 2011-03-24
AU2008339910A1 (en) 2009-07-02
KR101626416B1 (ko) 2016-06-01
SI2238168T1 (sl) 2014-09-30
CN101952315B (zh) 2015-04-01
EP2801584A1 (fr) 2014-11-12
KR20100100989A (ko) 2010-09-15
RU2010130994A (ru) 2012-02-10
PL2801584T3 (pl) 2019-12-31
EP2238168B1 (fr) 2014-06-11
EP2238168A1 (fr) 2010-10-13
PT2238168E (pt) 2014-07-18
RU2537265C2 (ru) 2014-12-27
MX2010007100A (es) 2010-12-06
ES2748299T3 (es) 2020-03-16
US20160185854A1 (en) 2016-06-30
TW200934511A (en) 2009-08-16
EP2238168B8 (fr) 2014-07-23
HK1149033A1 (en) 2011-09-23
CR11593A (es) 2011-06-07
MX341344B (es) 2016-08-16
IL206554A0 (en) 2010-12-30
CA2710453A1 (fr) 2009-07-02
AR069981A1 (es) 2010-03-03
TWI552759B (zh) 2016-10-11

Similar Documents

Publication Publication Date Title
ES2475201T3 (es) Agentes dirigidos contra CD138 y usos de los mismos
ES2526433T3 (es) Inmunoconjugados dirigidos a CD138 y usos de los mismos
US9446146B2 (en) Methods and agents for improving targeting of CD138 expressing tumor cells
AU2013203245A1 (en) Agents targeting CD138 and uses thereof
AU2013204492A1 (en) Immunoconjugates targeting CD138 and uses thereof